Sigyn Therapeutics Files 10-Q for Q3 2024
Ticker: SIGY · Form: 10-Q · Filed: Nov 19, 2024 · CIK: 1642159
| Field | Detail |
|---|---|
| Company | Sigyn Therapeutics, Inc. (SIGY) |
| Form Type | 10-Q |
| Filed Date | Nov 19, 2024 |
| Risk Level | low |
| Pages | 15 |
| Reading Time | 18 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, quarterly-report, company-information
TL;DR
**Sigyn Therapeutics 10-Q filed. Q3 2024 update.**
AI Summary
Sigyn Therapeutics, Inc. filed a 10-Q for the period ending September 30, 2024. The company, formerly known as Reign Resources Corp and Reign Sapphire Corp, is incorporated in Delaware and operates in the Surgical & Medical Instruments & Apparatus sector. Their business address is in Beverly Hills, California.
Why It Matters
This filing provides an update on Sigyn Therapeutics' financial performance and operational status for the third quarter of 2024, which is crucial for investors to assess the company's progress.
Risk Assessment
Risk Level: low — This is a standard quarterly filing (10-Q) and does not contain immediate, high-impact news.
Key Players & Entities
- Sigyn Therapeutics, Inc. (company) — Filer
- Reign Resources Corp (company) — Former company name
- Reign Sapphire Corp (company) — Former company name
- 20240930 (date) — Period of report
- 20241119 (date) — Filing date
FAQ
What is the reporting period for this 10-Q filing?
The 10-Q filing is for the period of report ending September 30, 2024.
When was this 10-Q filed with the SEC?
This 10-Q was filed on November 19, 2024.
What were Sigyn Therapeutics' former company names?
Sigyn Therapeutics, Inc. was formerly known as Reign Resources Corp and Reign Sapphire Corp.
In which state is Sigyn Therapeutics, Inc. incorporated?
Sigyn Therapeutics, Inc. is incorporated in Delaware (DE).
What is Sigyn Therapeutics' business address?
Sigyn Therapeutics' business address is 9190 W Olympic Blvd # 263, Beverly Hills, CA 90212.
Filing Stats: 4,511 words · 18 min read · ~15 pages · Grade level 19.1 · Accepted 2024-11-19 16:57:33
Key Financial Figures
- $0.0001 — ction 12(g) of the Act: Common Stock, $0.0001 Par Value Indicate by check mark whet
Filing Documents
- form10-q.htm (10-Q) — 1227KB
- ex10-1.htm (EX-10.1) — 12KB
- ex10-2.htm (EX-10.2) — 37KB
- ex31-1.htm (EX-31.1) — 12KB
- ex31-2.htm (EX-31.2) — 12KB
- ex32-1.htm (EX-32.1) — 8KB
- ex32-2.htm (EX-32.2) — 8KB
- 0001493152-24-046847.txt ( ) — 5693KB
- sigy-20240930.xsd (EX-101.SCH) — 38KB
- sigy-20240930_cal.xml (EX-101.CAL) — 45KB
- sigy-20240930_def.xml (EX-101.DEF) — 132KB
- sigy-20240930_lab.xml (EX-101.LAB) — 345KB
- sigy-20240930_pre.xml (EX-101.PRE) — 266KB
- form10-q_htm.xml (XML) — 910KB
– FINANCIAL INFORMATION
PART I – FINANCIAL INFORMATION Item 1.
Financial Statements
Financial Statements 4 Unaudited Condensed Consolidated Balance Sheets as of September 30, 2024 and December 31, 2023 4 Unaudited Condensed Consolidated Statements of Operations for the Three and Nine months ended September 30, 2024 and 2023 5 Unaudited Condensed Consolidated Statements of Stockholders' Deficit for the Three and Nine months ended September 30, 2024 and 2023 6 Unaudited Condensed Consolidated Statements of Cash Flows for the Nine months ended September 30, 2024 and 2023 7 Notes to the Unaudited Condensed Consolidated Financial Statements 8 Item 2.
Management's Discussion and Analysis of Financial Condition and Results of Operations
Management's Discussion and Analysis of Financial Condition and Results of Operations 24 Item 3.
Quantitative and Qualitative Disclosures About Market Risk
Quantitative and Qualitative Disclosures About Market Risk 42 Item 4.
Controls and Procedures
Controls and Procedures 42
– OTHER INFORMATION
PART II – OTHER INFORMATION Item 1.
Legal Proceedings
Legal Proceedings 43 Item1A.
Risk Factors
Risk Factors 43 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 44 Item 3. Defaults Upon Senior Securities 44 Item 4. Mine Safety Disclosure 44 Item 5. Other Information 44 Item 6. Exhibits 44
SIGNATURES
SIGNATURES 45 2 DISCLOSURE REGARDING FORWARD LOOKING STATEMENTS This report contains forward-looking statements. The forward-looking statements are contained principally in the sections entitled "Description of Business," "Risk Factors," and "Management's Discussion and Analysis of Financial Condition and Results of Operations." These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "anticipates," "believes," "seeks," "could," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "projects," "should," "would" and similar expressions intended to identify forward-looking statements. Forward-looking statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: the ability of Sigyn to meet its financial and strategic goals, due to, among other things, competition; the ability of Sigyn to grow and manage growth profitability and retain its key employees; the possibility that the Sigyn may be adversely affected by other economic, business, and/or competitive factors; risks relating to the successful development of Sigyn's product candidates; the ability to successfully complete planned clinical studies of its product candidates; the risk that we may not fully enroll our clinical studies or enrollment will take longer than expected; risks relating to the occurrence of adverse safety events and/or unexpected concerns that may arise from data or analysis from our clinical studies; changes in applicable laws or regulations; expected ini